Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

Interventions

DRUG: Tucatinib
DRUG: Eribulin
DRUG: Trastuzumab

Sponsor

Criterium, Inc.